Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > old enough to remember

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Jun 10, 2024 8:36am

164 Views

Post# 36080543

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:old enough to remember

"They" hate the Covid "excuse" and believed it should have been business as usual for ongoing research in ICU's as soon as the final wave subsided.

On the positive side it's notable that a recent study finds that PMX has been used to successfully treat a certain group of Covid patients. Hemopurfusion will likely apply to future nasty viral outbreaks WHEN indeed it happens again. So perhaps the unavoidable delays will, in a sense, ultimately prove to be a blessing in disguise for whomever owns the NA rights to PMX and EAA in the future.

MM

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario